Investigation on the occurrence of anorexigens, benzodiazepines and antidepressants in the weight-reducer phytotherapy formulations
Several weight-reducer phytotherapic formulations commercialized in Brazil contain undeclared synthetic drugs. This situation constitutes a public health issue for the country. This study aimed at evaluating the occurrence of anorexigenic, benzodiazepinic and antidepressant drugs in the phytopharmac...
| Authors: | , , , , , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2012 |
| Country: | Brasil |
| Institution: | Instituto Adolfo Lutz |
| Repository: | Revista do Instituto Adolfo Lutz (Online) |
| Language: | Portuguese |
| OAI Identifier: | oai:ojs.periodicos.saude.sp.gov.br:article/32404 |
| Online Access: | https://periodicos.saude.sp.gov.br/RIAL/article/view/32404 |
| Access Level: | Open access |
| Keyword: | adulteration phytomedicines anorexigens anxyolytics antidepressants adulteração formulação fitoterápica anorexígenos ansiolíticos antidepressivos |
| Summary: | Several weight-reducer phytotherapic formulations commercialized in Brazil contain undeclared synthetic drugs. This situation constitutes a public health issue for the country. This study aimed at evaluating the occurrence of anorexigenic, benzodiazepinic and antidepressant drugs in the phytopharmaceutical preparations monitored and collected by the Public Health Surveillance of the State of Minas Gerais, Brazil. By chemical tests, the absence of at least one class of the analyzed secondary metabolites (flavonoids, saponins and quinones) was found in all analyzed samples. Fenproporex, fluoxetine and chlordiazepoxide, alone or in association, were identified by GC-MS in all formulations. Therefore, the analyzed samples did not comply with the established quality standards, as these formulations contain undeclared synthetic compounds in their compositions, along with the association of anorexigens and anxiolytics drugs, which are not allowed by the Brazilian sanitary legislation. Hence, a more effective quality control of the weight-reducer phytotherapy formulations is demanded, as well as improving educational actions addressed to health professionals and consumers. |
|---|